GREY:IPHAF - Post by User
Comment by
blogon Oct 26, 2006 4:10pm
256 Views
Post# 11563169
RE: none
RE: noneAGhostRider,
I would imagine this drug for the psoriasis indication is worth between 100mil and 200mil in peak sales. It will be interesting to see what happens. Isotechnika paid about 20mil to get the rights back from Roche + Roch doesn't pay 70% of drug trial costs going forward + Roche is not pot committed anymore, its easier for them to walk away unless they get the results wanted from renal. It will all sort itself out shortly IMO.